Lifecore Biomedical Stock Price To Book

LFCR Stock

6.58 0.07 1.05%

Lifecore Biomedical fundamentals help investors to digest information that contributes to Lifecore Biomedical's financial success or failures. It also enables traders to predict the movement of Lifecore Stock. The fundamental analysis module provides a way to measure Lifecore Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lifecore Biomedical stock.

Short Long Term Debt Total Total Assets

As of 03/21/2025, Price To Book Ratio is likely to grow to 0.74.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Lifecore Biomedical Company Price To Book Analysis

Lifecore Biomedical's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Current Lifecore Biomedical Price To Book

15.75 X

Most of Lifecore Biomedical's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lifecore Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Lifecore Price To Book Driver Correlations

Understanding the fundamental principles of building solid financial models for Lifecore Biomedical is extremely important. It helps to project a fair market value of Lifecore Stock properly, considering its historical fundamentals such as Price To Book. Since Lifecore Biomedical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lifecore Biomedical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lifecore Biomedical's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Net Receivables	Intangible Assets	Common Stock	Current Deferred Revenue	Short Term Investments	Good Will	Net Tangible Assets	Long Term Debt	Net Invested Capital	Long Term Investments	Short Long Term Debt	Capital Stock	Net Working Capital	Property Plant Equipment
Total Assets		0.76	0.62	0.48	0.75	0.69	0.85	0.4	0.89	0.31	-0.66	-0.48	-0.66	0.69	0.24	0.21	0.25	0.04	0.26	-0.2	-0.08	0.15
Total Stockholder Equity	0.76		0.0	0.91	0.8	0.08	0.45	0.17	0.77	0.63	-0.42	-0.46	-0.64	0.89	0.72	-0.34	0.71	0.63	0.69	-0.61	-0.6	0.66
Net Debt	0.62	0.0		-0.28	0.16	0.94	0.84	0.56	0.46	-0.31	-0.41	-0.21	-0.24	0.02	-0.44	0.67	-0.41	-0.67	-0.38	0.31	0.6	-0.53
Retained Earnings	0.48	0.91	-0.28		0.6	-0.27	0.22	0.11	0.52	0.72	-0.09	-0.38	-0.46	0.87	0.9	-0.55	0.87	0.83	0.86	-0.82	-0.75	0.83
Accounts Payable	0.75	0.8	0.16	0.6		0.32	0.48	0.2	0.89	0.53	-0.5	-0.46	-0.54	0.71	0.4	-0.33	0.48	0.48	0.57	-0.28	-0.56	0.58
Total Liab	0.69	0.08	0.94	-0.27	0.32		0.78	0.38	0.53	-0.22	-0.57	-0.25	-0.3	0.09	-0.43	0.69	-0.37	-0.62	-0.37	0.4	0.49	-0.48
Total Current Assets	0.85	0.45	0.84	0.22	0.48	0.78		0.69	0.76	0.16	-0.56	-0.47	-0.56	0.39	-0.02	0.35	-0.05	-0.29	0.03	-0.08	0.28	-0.15
Short Term Debt	0.4	0.17	0.56	0.11	0.2	0.38	0.69		0.44	-0.03	-0.2	-0.33	-0.31	0.05	-0.21	-0.03	-0.26	-0.19	-0.05	-0.13	0.29	-0.09
Net Receivables	0.89	0.77	0.46	0.52	0.89	0.53	0.76	0.44		0.34	-0.66	-0.53	-0.69	0.6	0.25	-0.14	0.27	0.19	0.41	-0.22	-0.25	0.32
Intangible Assets	0.31	0.63	-0.31	0.72	0.53	-0.22	0.16	-0.03	0.34		-0.19	-0.48	-0.43	0.68	0.71	-0.39	0.69	0.65	0.66	-0.59	-0.61	0.65
Common Stock	-0.66	-0.42	-0.41	-0.09	-0.5	-0.57	-0.56	-0.2	-0.66	-0.19		0.5	0.83	-0.16	0.17	-0.17	0.17	0.21	0.16	-0.13	-0.19	0.18
Current Deferred Revenue	-0.48	-0.46	-0.21	-0.38	-0.46	-0.25	-0.47	-0.33	-0.53	-0.48	0.5		0.57	-0.41	-0.24	0.18	-0.25	-0.19	-0.31	0.26	0.18	-0.25
Short Term Investments	-0.66	-0.64	-0.24	-0.46	-0.54	-0.3	-0.56	-0.31	-0.69	-0.43	0.83	0.57		-0.39	-0.18	0.13	-0.14	-0.13	-0.18	0.42	0.06	-0.14
Good Will	0.69	0.89	0.02	0.87	0.71	0.09	0.39	0.05	0.6	0.68	-0.16	-0.41	-0.39		0.81	-0.19	0.83	0.66	0.75	-0.63	-0.66	0.71
Net Tangible Assets	0.24	0.72	-0.44	0.9	0.4	-0.43	-0.02	-0.21	0.25	0.71	0.17	-0.24	-0.18	0.81		-0.49	0.97	0.85	0.91	-0.77	-0.81	0.84
Long Term Debt	0.21	-0.34	0.67	-0.55	-0.33	0.69	0.35	-0.03	-0.14	-0.39	-0.17	0.18	0.13	-0.19	-0.49		-0.47	-0.8	-0.65	0.53	0.73	-0.76
Net Invested Capital	0.25	0.71	-0.41	0.87	0.48	-0.37	-0.05	-0.26	0.27	0.69	0.17	-0.25	-0.14	0.83	0.97	-0.47		0.87	0.91	-0.72	-0.88	0.87
Long Term Investments	0.04	0.63	-0.67	0.83	0.48	-0.62	-0.29	-0.19	0.19	0.65	0.21	-0.19	-0.13	0.66	0.85	-0.8	0.87		0.88	-0.72	-0.96	0.97
Short Long Term Debt	0.26	0.69	-0.38	0.86	0.57	-0.37	0.03	-0.05	0.41	0.66	0.16	-0.31	-0.18	0.75	0.91	-0.65	0.91	0.88		-0.72	-0.9	0.94
Capital Stock	-0.2	-0.61	0.31	-0.82	-0.28	0.4	-0.08	-0.13	-0.22	-0.59	-0.13	0.26	0.42	-0.63	-0.77	0.53	-0.72	-0.72	-0.72		0.59	-0.71
Net Working Capital	-0.08	-0.6	0.6	-0.75	-0.56	0.49	0.28	0.29	-0.25	-0.61	-0.19	0.18	0.06	-0.66	-0.81	0.73	-0.88	-0.96	-0.9	0.59		-0.97
Property Plant Equipment	0.15	0.66	-0.53	0.83	0.58	-0.48	-0.15	-0.09	0.32	0.65	0.18	-0.25	-0.14	0.71	0.84	-0.76	0.87	0.97	0.94	-0.71	-0.97

Click cells to compare fundamentals

Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Competition

Predict Lifecore Biomedical

Price Book Value Ratio Over Time

Based on the latest financial disclosure, Lifecore Biomedical has a Price To Book of 15.7458 times. This is 38.68% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The price to book for all United States stocks is 65.57% lower than that of the firm.

Lifecore Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lifecore Biomedical's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lifecore Biomedical could also be used in its relative valuation, which is a method of valuing Lifecore Biomedical by comparing valuation metrics of similar companies.

Lifecore Biomedical is currently under evaluation in price to book category among its peers.

Lifecore Biomedical ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lifecore Biomedical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lifecore Biomedical's managers, analysts, and investors.

Environmental

Governance

Social

Lifecore Fundamentals

	Return On Equity	-0.3
	Return On Asset	-0.0247
	Profit Margin	(0.11) %
	Operating Margin	(0.05) %
	Current Valuation	365.14 M
	Shares Outstanding	37.03 M
	Shares Owned By Insiders	4.52 %
	Shares Owned By Institutions	73.59 %
	Number Of Shares Shorted	2.4 M
	Price To Book	15.75 X
	Price To Sales	1.88 X
	Revenue	128.26 M
	Gross Profit	45.64 M
	EBITDA	35.6 M
	Net Income	9.33 M
	Total Debt	130.36 M
	Book Value Per Share	0.42 X
	Cash Flow From Operations	(217 K)
	Short Ratio	19.93 X
	Earnings Per Share	(0.56) X
	Price To Earnings To Growth	3.51 X
	Target Price	10.0
	Number Of Employees	524
	Beta	0.97
	Market Capitalization	246.22 M
	Total Asset	273.7 M
	Retained Earnings	(166.52 M)
	Working Capital	42.16 M
	Net Asset	273.7 M

About Lifecore Biomedical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lifecore Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lifecore Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lifecore Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Additional Tools for Lifecore Stock Analysis

When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC